Vertex Pharmaceuticals Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 11/29/2023
Vertex Pharmaceuticals Inc Stock Forecast and Price Target
The average target price for Vertex Pharmaceuticals Inc's stock set by eighteen renowned analysts in recent months is $390.00, representing a potential upside of approximately 12.38% from its last closing price if met by 2024. This estimation is based on a high estimate of $456.00 and a low estimate of $314.00. Even if you are not interested in VRTX stock, it is still imperative to be aware of its competitors.
12.38% Upside
Vertex Pharmaceuticals Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Price for Vertex Pharmaceuticals Inc has grown by 179.17%, going from $149.61 to $417.68. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $436.49 – an increase of 4.50%. Over the next eight years, experts anticipate that Fair Value growth for Vertex Pharmaceuticals Inc will be 52.76%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
16
|
$591.60 | Buy/Sell | $594.01 | 9.87% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$151.63 | Buy/Sell | $176.14 | 13.43% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$100.18 | Buy/Sell | $123.75 | 24.78% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$29.69 | Buy/Sell | $40.55 | 26.31% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$48.92 | Buy/Sell | $64.26 | 25.72% |
Vertex Pharmaceuticals Inc Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Revenue for Vertex Pharmaceuticals Inc has grown by 114.54%, going from $4.16B to $8.93B. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach $9.24B – an increase of 3.42%. Over the next eight years, experts anticipate that Revenue growth for Vertex Pharmaceuticals Inc will be 43.87%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$801.14 | Buy/Sell | $796.73 | 14.09% |
| ZTS Stock Forecast | Zoetis Inc | Outperform |
18
|
$176.97 | Buy/Sell | $217.57 | 18.66% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$161.36 | Buy/Sell | $245.24 | 42.54% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$36.34 | Buy/Sell | $45.50 | 22.45% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$9.14 | Buy/Sell | $11.74 | 25.82% |
| UTHR Stock Forecast | United Therapeutics Corp | Outperform |
12
|
$230.39 | Buy/Sell | $278.82 | 30.21% |
Vertex Pharmaceuticals Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Vertex Pharmaceuticals Inc's Free Cash Flow has grown, increasing from $1.49B to $3.89B – an increase of 160.72%. According to 7 prominent analysts, Vertex Pharmaceuticals Inc's Free Cash Flow will fall by 1.41% in the next year, reaching $3.84B. Over the next eight years, the pros' prediction is Free Cash Flowof $6.40B, which would mean a eight-year growth forecast of 64.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IONS Stock Forecast | Ionis Pharmaceuticals Inc | Outperform |
9
|
$48.34 | Buy/Sell | $51.20 | 24.12% |
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$39.46 | Buy/Sell | $49.29 | 21.64% |
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$30.46 | Buy/Sell | $45.67 | 44.45% |
Vertex Pharmaceuticals Inc Net Income Forecast for 2023 - 2025 - 2030
In the last three years, Vertex Pharmaceuticals Inc's Net Income has increased by 182.29%, going from $1.18B to $3.32B. In the next year, analysts are expecting an increase in Net Income, predicting it will reach $4.05B – an increase of 22.04%. The Vertex Pharmaceuticals Inc forecast is for Net Income to reach $6.01B or grow by 80.89%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$122.71 | Buy/Sell | $145.00 | 22.24% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$190.94 | Buy/Sell | $170.08 | 73.09% |
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$16.60 | Buy/Sell | $37.00 | 34.04% |
Vertex Pharmaceuticals Inc EBITDA Forecast for 2023 - 2025 - 2030
Vertex Pharmaceuticals Inc's EBITDA has increased by 245.84% In the last three years, going from $1.31B to $4.53B. In the next year, analysts expect EBITDA to reach $5.57B – an increase of 22.96%. For the next eight years, the forecast is for EBITDA to grow by 28.19%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CYTK Stock Forecast | Cytokinetics Inc | Outperform |
10
|
$31.22 | Buy/Sell | $61.75 | 92.18% |
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$54.41 | Buy/Sell | $69.00 | 21.30% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$25.45 | Buy/Sell | $0.00 | 41.45% |
Vertex Pharmaceuticals Inc EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Vertex Pharmaceuticals Inc's EBIT has grown, increasing from $1.20B to $4.38B – a growth of 264.26%. The next year looks promising for Vertex Pharmaceuticals Inc, with analysts predicting EBIT of $5.07B – an increase of 15.83%. Over the next eight years, experts anticipate that Vertex Pharmaceuticals Inc's EBIT will grow at a rate of 66.85%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£12.38 | Buy/Sell | £3.79 | 134.25% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$12.63 | Buy/Sell | $26.83 | 90.02% |
| CPRX Stock Forecast | Catalyst Pharmaceuticals | Outperform |
16
|
$14.21 | Buy/Sell | $23.30 | 75.93% |
Vertex Pharmaceuticals Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, EPS for Vertex Pharmaceuticals Inc has grown by 179.17%, going from $5.33 to $14.88. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $15.55 – an increase of 4.50%. Over the next eight years, experts anticipate that EPS growth for Vertex Pharmaceuticals Inc will be 52.76%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Outperform |
14
|
$9.68 | Buy/Sell | $17.40 | 106.61% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$26.97 | Buy/Sell | $41.00 | 53.87% |
| ARPO Stock Forecast | Aerpio Pharmaceuticals | - |
6
|
$30.30 | Buy/Sell | $0.00 | -100.00% |
Site Navigation
.jpg)